This study tests a new treatment called **IDP-023** for people with serious blood cancers. Blood cancers are diseases where the blood cells grow out of control. IDP-023 uses "natural killer" cells. These are a type of white blood cell that can attack cancer cells. In this study, IDP-023 is given alone or with other treatments like interleukin-2 (IL-2), isatuximab, daratumumab, or rituximab. The study has two parts:
Phase 1 - Checks if the treatment is safe and finds the best dose. Phase 2 - Tests how well the treatment works.
**Key Points**:
- This study is only for patients with advanced multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) who have tried other treatments without success.
- Participants must not have serious heart issues, infections like HIV, or untreated brain cancer.
- Participants should be able to do normal daily activities and have a life expectancy of more than 12 weeks.
People considering this study should know it involves multiple visits and tests to monitor safety and effectiveness.
How understandable was the trial content above?
Hard to understand
Easy to understand